Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 12/20 | 1.00 |
| ▸ | ADH1C | P00326 | 9/20 | 0.96 |
| ▸ | ADH4 | P08319 | 3/20 | 0.58 |
| ▸ | ADH1B | P00325 | 2/20 | 0.44 |
| ▸ | ADH7 | P40394 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 5/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | DRD4 | P21917 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9660553 | 1.00 | ADH1A (1.00) | ADH1AADH1CADH4ADH1BADH7 | |
| SCHEMBL9661004 | 1.00 | ADH1A (1.00) | ADH1AADH1CADH4ADH1BADH7 | |
| Hydrochloric Acid SCHEMBL8308886 | 0.98 | ADH1A (0.96) | ADH1AADH1CADH4ADH1BADH7 | |
| SCHEMBL7802361 | 0.98 | ADH1A (1.00) | ADH1AADH1CADH4ADH1BDRD3 | |
| Hydrochloric Acid SCHEMBL8303801 | 0.96 | ADH1A (0.96) | ADH1AADH1CADH4ADH1BDRD3 | |
| SCHEMBL8383244 | 0.96 | ADH1A (0.96) | ADH1AADH1CADH4ADH1BDRD3 | |
| SCHEMBL1678410 | 0.89 | — | — | |
| SCHEMBL9658881 | 0.88 | ADH1A (0.79) | ADH1AADH1CADH4ADH1BADH7 | |
| SCHEMBL726395 | 0.88 | ADH1A (0.79) | ADH1AADH1CADH4ADH1BADH7 | |
| SCHEMBL9660884 | 0.88 | ADH1A (0.79) | ADH1AADH1CADH4ADH1BADH7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3390372-B1 | BENZAMIDE COMPOUNDS AND THEIR USE AS HERBICIDES | BASF SE (DE) | 2020-06-03 | — | — | EP | disclosed |
| EP-1027351-B1 | PHENANTHROLINE DERIVATIVES | FIBROGEN INC (US) | 2003-12-03 | — | — | EP | disclosed |
| US-20010001101-A1 | Phenanthroline derivatives | ZENECA LIMITED | 2001-05-10 | — | — | US | disclosed |
| US-6200974-B1 | FOR PRODUCING AN ANTI-FIBROPROLIFERATIVE EFFECT | ZENECA LIMITED (GB) | 2001-03-13 | — | — | US | disclosed |
| US-5916898-A | ANTIFIBROPROLIFERTIVE, ENZYME INHIBITORS OF PYROLYL 4-HYDROXYLASE, ANTIARTHRITIC AGENTS | ZENECA LIMITED (GB) | 1999-06-29 | — | — | US | disclosed |
| US-5861429-A | MITICIDES AND ANTHELMINTICS | SANKYO COMPANY, LIMITED (JP) | 1999-01-19 | — | — | US | disclosed |
| WO-1997047599-A1 | SUCCINAMIDE DERIVATIVES USEFUL AS TNF- AND/OR MMP INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-12-18 | — | — | WO | disclosed |
| US-5656604-A | HYPOTENSIVE AGENT; ENDOTHELIN ANTAGONIST | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-12 | — | — | US | disclosed |
| US-5430022-A | Endothelin antagonists; hypotensive agents; treatment for angina pectoris, brain disorders, asthma, renal failure | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-07-04 | — | — | US | disclosed |
| US-5284828-A | Hypotensive agents | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 1994-02-08 | — | — | US | disclosed |
| US-5224987-A | Aqueous carriers with colors and tertiary amide penetrants | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-07-06 | — | — | US | disclosed |
| EP-0517262-A1 | Trifluorothymidine derivatives, process for producing the same and anti-cancer agent containing the same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1992-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010001101-A1 | Phenanthroline derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, COL1A1, COL2A1 | ADH1A 293/4885ADH1C 24/4885ADH4 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.